ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis 2Q Net Profit Up Marginally, Beating Expectations

By Marta Falconi ZURICH--Swiss drug maker Novartis AG (NVS) said Thursday its net profit rose slightly in the second quarter, helped by the good performance of its eye care unit and the flagship pharmaceutical division, which helped offset weaker sales of blockbuster drug Diovan, which was hurt by increased generics competition. The Basel-based company said it is on track to deliver 2012 full-year outlook after net profit for the three months to the end of June edged up to $2.71 billion from $2.70 billion in the same period a year earlier, above analysts' expectations of $2.52 billion. Net sales were down 4% at $14.3 billion, hurt by increased competition for the company's generic unit Sandoz and the continued drag from the suspension of production at a factory in Lincoln, Nebraska. Sales at the flagship pharmaceuticals division decreased 1% to $8.3 billion. Write to Marta Falconi at marta.falconi@dowjones.com Order free Annual Report for Novartis AG Visit http://djnweurope.ar.wilink.com/?ticker=CH0012005267 or call +44 (0)208 391 6028 Order free Annual Report for Novartis AG Visit http://djnweurope.ar.wilink.com/?ticker=US66987V1098 or call +44 (0)208 391 6028 Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Novartis (NVS)
DateTimeHeadline
12/16/201403:22:10Novartis Gets U.S. Approval for Hormonal Disorder Drug
12/12/201418:22:53Novartis: Afinitor Fails to Make a Significant Treatment Difference
12/03/201423:43:31Array BioPharma to Regain Global Rights to Cancer Therapy
12/03/201423:42:41Array BioPharma to Regain Global Rights to Cancer Therapy From...
11/26/201418:31:46Novartis to Divest Nicotine Patch Habitrol to Comply with FTC
11/21/201402:39:34Novartis Psoriasis Treatment Recommended for Approval by CHMP
11/06/201407:57:33Biosimilars: The Good, the Bad and the Unknown -- Barron's
10/29/201411:53:10Norway's Oil Fund Posts Flat Returns in 3Q
10/29/201411:13:35Norway's Oil Fund Posts Flat Returns in 3Q--Update
10/28/201413:20:12EUROPE MARKETS: European Stocks Rebound; Stoxx 600 Up 1%
10/28/201406:05:25EUROPE MARKETS: European Stocks Rebound; Stoxx 600 Up 0.7%
10/26/201422:31:12CSL to Buy Novartis Influenza-Vaccine Unit
10/26/201418:49:15CSL to Buy Novartis Influenza-Vaccine Unit for $275 Million
10/23/201407:33:40Novartis 3Q 2014 -- Forecast
10/10/201404:08:25Oxford Biomedica Inks New Collaboration Pact with Novartis
10/03/201411:32:27EU Approves Acquisition of Novartis Animal Health Division by...
09/22/201412:43:39Germany's Merck to Buy Sigma-Aldrich for $17 Billion--2nd Update
09/01/201412:45:13EUROPE MARKETS: Novartis Climbs, Iliad Drops: European Movers
09/01/201412:01:47EUROPE MARKETS: Novartis Up, Iliad Drops: European Movers
09/01/201408:27:44Ruble Hits New Record Low Against Dollar

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad